Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute.

Join us as we explored:

The critical distinction between primary and secondary myelofibrosis and its implications for treatment
The essential workup needed before initiating therapy, including bone marrow biopsy and mutation analysis
Anemia management strategies, including the use of erythropoiesis-stimulating agents and the innovative drug luspatercept
The role of JAK inhibitors in treatment, including ruxolitinib, momelotinib, pacritinib, and fedratinib, and how to choose among them based on patient needs
The importance of spleen reduction and its correlation with patient outcomes and survival
Insights into the side effect profiles of various treatments and the future of myelofibrosis management

Whether you're a healthcare professional or someone interested in oncology, this episode provides valuable information on navigating the complexities of myelofibrosis treatment.

Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o

Follow us on social media:

•⁠ ⁠X/Twitter: https://x.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/

Don't forget to like, subscribe, and hit the notification bell for more episodes from the Oncology Brothers!

#Myelofibrosis, #JAKinhibitors, #Hematology, #MPN, #OncologyBrothers

Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann

Oncology Brothers: Practice-Changing Cancer Discussions

Myelofibrosis Treatment Algorithm Discussion: Dr. Nico Gagelmann